The short answer patients usually need first

ChondroFiller's collagen scaffold is designed to dissolve — and that is precisely how it works. Over roughly 6 to 24 months, the gel is gradually resorbed by the body. This is not the treatment wearing off; it is the treatment doing its job.

The scaffold's purpose is to act as a biological template: a temporary structure that recruits the patient's own progenitor cells from the surrounding tissue and supports them as they mature into cartilage-like repair tissue. Once that process is underway, the repair becomes self-sustaining. The scaffold is no longer needed.

What patients are most often asking — 'how long will I feel better?' — has a different answer. Clinical evidence documents meaningful pain relief and improved joint function persisting for three to five years, and in some well-selected cases beyond that. ChondroFiller is a single-course treatment; there is no scheduled reinjection cycle to plan around. The gel dissolving and the benefit fading are simply not the same event.

Why the repair holds once the scaffold is gone

Think of the scaffold as temporary hoarding around a repair site. The hoarding comes down once the structure beneath can support itself — its removal is a sign of completion, not of failure.

The technical term for what ChondroFiller triggers is acellular matrix-induced chondrogenesis. The gel itself contains no donor cells; instead, its collagen structure creates an environment that draws progenitor cells inward from the synovium and subchondral bone. A 2025 ex vivo model measured this process directly: DNA content within the scaffold increased 2.4-fold within 14 days of implantation, confirming that host cell migration begins almost immediately rather than weeks later.

Those cells continue populating and maturing for considerably longer. Full resorption of the scaffold and its replacement by the patient's own cartilage-like repair tissue may continue for up to two years — which is also why published clinical scores tend to be marginally higher at 36 months than at 12 months. By the time the scaffold has gone, the tissue it supported has already taken structural responsibility. The biology, in short, does not depend on the scaffold still being present to hold the result in place.

What the published evidence shows at 3–5 years

The numbers from the published record translate the biology into patient-relevant terms. In the Jerosch et al. post-market clinical follow-up study — cited in the manufacturer's Clinical Evaluation Report (Version 09, April 2025) — patients recorded a mean IKDC score improvement of 32.4 points at 36 months, reaching an absolute score of 80.1 out of 100. The minimum clinically important difference (MCID) for the IKDC questionnaire is 16.7 points; the average gain at three years is roughly double that threshold, placing it well above what most patients would register as meaningful improvement.

The trajectory over time confounds the natural assumption that outcomes must erode — they consolidate instead. The 36-month improvement of 32.4 points sits marginally above the 12-month mean of approximately 30 points recorded across four independent prospective knee cohorts. Results are not declining; they are stabilising at a higher level.

The longest published follow-up currently available comes from the Mazek 2021 hip cohort (Journal of Hip Preservation Surgery). Of 21 evaluable patients treated for focal acetabular cartilage defects, 17 — 81% — had good or excellent results at three, four, and five consecutive years. Across the published evidence base as a whole, 70–85% of treated patients achieve meaningful symptom relief consistently at the three-to-five-year mark.

MRI data corroborate these patient-reported gains. MOCART scores of 70–87 in appropriately selected patients confirm objective defect filling and cartilage integration at the tissue level — not just symptom scores on a questionnaire.

Which patients tend to keep their results longest

The most important predictor of lasting benefit is the nature of the underlying joint problem, not symptom severity alone. ChondroFiller is designed for focal cartilage lesions — a discrete patch of damage in an otherwise structurally sound joint. Patients with diffuse, background wear-and-tear arthritis spread across the joint respond substantially less well, and the clinical evidence reflects this distinction explicitly.

The Mazek hip study, already noted for its five-year outcomes, makes the separation plain: patients with focal acetabular defects accounted for virtually all the good and excellent results, while those with pre-existing osteoarthritis at Tönnis grades 2–3 — indicating joint-wide degeneration rather than a contained lesion — had poor outcomes. Defect size, joint alignment, and activity level carry similar weight alongside that central distinction.

Evidence depth also varies by joint. The knee evidence base is the most mature; hip, ankle, and small-joint data are clinically meaningful but drawn from smaller cohorts. Over 19,000 procedures globally provide real-world breadth, though most published series remain small, which means individual characteristics still matter considerably in predicting how any given patient will fare.

That individual variation is precisely why the productive question is not "will this work?" but "does my joint fit the profile that tends to respond well?" A consultant evaluation — covering the extent of cartilage loss, joint condition, and degree of any background arthritis — is what places a patient within or outside the evidence profile.

The first six weeks: protecting the repair as it forms

Restricting activity for six weeks after an injection is rarely a popular instruction. For patients used to training or simply walking without pain, the early weight-protection phase can feel like the most demanding part of the treatment pathway — particularly when there is nothing visible to show for the caution.

The biomechanical reason is specific. A 2024 in vitro study found that ChondroFiller did not reduce damage to the opposing cartilage surface under cyclic joint loading in the immediate post-implantation period, because the scaffold had not yet stabilised within the defect. Before host cells begin to infiltrate and anchor the gel — a process confirmed to be underway within the first two weeks — the material cannot yet bear the mechanical demands of normal movement. Loading the joint in this window risks disrupting the scaffold before the repair can consolidate.

Scaffold instability at this stage is not a sign that the treatment is failing; it is the normal state of the early repair phase. The six-week protection window exists to preserve conditions that allow cell migration to take hold. Once that threshold is passed, graded loading is reintroduced progressively, and tissue maturation continues for up to two years. The restriction is, in effect, the first clinical decision in a long-term outcome.

What the evidence does not yet cover — and what to ask

Five years marks the practical horizon of the current evidence. Published outcomes show maintained benefit to that point for well-selected patients, but data beyond that window are limited — not because problems have emerged, but simply because the longest cohorts have not run further yet. Most published series are also small, and the majority carry some connection to the manufacturer's post-market programme; large independent randomised controlled trials with extended follow-up have not been completed for ChondroFiller.

Those gaps translate directly into questions worth raising with a consultant before proceeding. What is the defect size, and does it sit within the range studied in published cohorts? Is there any background degeneration beyond the focal lesion — and if so, how does that change the expected trajectory? How does the clinician interpret the three-to-five-year evidence horizon for the specific joint involved, and at what point would a follow-up assessment be appropriate?

For patients comparing options, hyaluronic acid viscosupplementation typically provides around three to six months of symptom relief per course and requires repeat dosing indefinitely. ChondroFiller is designed as a single course, with the scaffold's work front-loaded rather than ongoing — a practical distinction when planning over the medium term.

A consultant assessment at MSK Doctors, available without a GP referral, is where those specific questions can be answered against individual imaging and history at mskdoctors.com.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Implantation of ChondroFiller Liquid® as a Scaffold for Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
6. [6] Influence of cartilage defects and collagen gel on integrity of corresponding cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z